Senate Passes Food & Drug Administration Reauthorization Act (FDARA)

Update on FDARA passage from Life Science Washington

As you may have heard, yesterday the U.S. Senate passed the Food and Drug Reauthorization Act (FDARA) which reauthorizes the pharmaceutical, medical device, generic drug, and biosimilar user fee agreements that expire at the end of September.

The Senate took a thoughtful and bipartisan approach to FDA Reauthorization, which will accelerate medical innovation, increase patient involvement in the regulatory process, and ultimately provide patients with better healthcare outcomes. Life Science Washington commends the Senate for completing work on this important legislation.The bill will go to the President next to be signed into law. Life Science Washington continues to play an active role in advocating for public policies that foster industry innovation and improve the lives of patients in our own communities and beyond.

Please click here to read BIO's statement on the Senate passage. We will continue to update our membership on important policy developments at state and federal levels as they happen. To learn more about our advocacy work, please contact Marc Cummings, Vice President of Public Policy and External Affairs at or (206) 456-9566.